What is Wall Street's Target Price for Jounce Therapeutics Inc (JNCE) Stock Monday?

Monday, March 27, 2023 03:55 PM | InvestorsObserver Analysts

Mentioned in this article

Wall Street is positive on Jounce Therapeutics Inc (JNCE). On average, analysts give the stock a Buy rating. The average price target is $6, which means analysts expect the stock to add by 226.09% over the next twelve months. That average ranking earns the stock an Analyst Rating of 26, which is better than 26% of stocks based on data compiled by InvestorsObserver.

Wall Street analysts are rating JNCE a Buy today. Find out what this means to you and get the rest of the rankings on JNCE!
See Full JNCE Report

Why are Analyst Ratings Important?

Analytical research by professionals can be extremely useful when making investment decisions in the stock market. Analysts are able to observe industries in detail and learn how geographical impacts can affect a company's balance sheet. This information allows investors to make decisions ahead of the curve. InvestorsObserver combines the ratings from these analysts and proceeds to percentile rank them. This grants you the ability to compare stocks in a comprehensive fashion as oppossed to a standard buy/hold/sell rating.

What's Happening With Jounce Therapeutics Inc Stock Today?

Jounce Therapeutics Inc (JNCE) stock is trading at $1.84 as of 3:54 PM on Monday, Mar 27, a rise of $0.33, or 21.85% from the previous closing price of $1.51. The stock has traded between $1.83 and $1.90 so far today. Volume today is above average. So far 13,885,973 shares have traded compared to average volume of 3,770,312 shares. Click Here to get the full Stock Report for Jounce Therapeutics Inc stock.

Share this article:

Related Articles